Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral AgentRaju Subramanian, Bill J. Smith, George Stepan et al.|Molecular Pharmaceutics|2023Cited by 52
539. GS-CA2: A Novel, Potent, and Selective First-In-class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in HumansJim Zheng, Winston C. Tse, Stephen R. Yant et al.|Open Forum Infectious Diseases|2018Cited by 15
Discovery ofLenacapavir: First-in-Class Twice-YearlyCapsid Inhibitor for HIV-1 Treatment and Pre-exposure ProphylaxisEda Canales, John O. Link, Winston C. Tse et al.|Journal of Medicinal Chemistry|2025Cited by 11